Table 4.
Post-thaw CD34+ and 7-AAD viability*** percentage of ex vivo expanded pharmacologically preconditioned UCB-HSCs
| CD34+-PE % | |||||
|
| |||||
| Exp# | 1 | 2 | 3 | 4 | Mean +/- SD |
|
| |||||
| Post-Thawing Day 0 | 3, 66 | 0, 23 | 0, 32 | 4, 27 | 2.12 +/- 2.14 |
| Post-Expansion Day 8 | 21, 95 | 2, 24 | 2, 81 | 21, 79 | 12.19 +/- 11.17 |
| Fold Expansion | 5, 99 | 9, 73 | 8, 78 | 5, 1 | 7.4 +/- 2.20 |
|
| |||||
| VIABILITY 7-AAD-/% | |||||
|
| |||||
| Exp# | 1 | 2 | 3 | 4 | Mean +/- SD, p*** < 0.05 |
|
| |||||
| Post-Thawing Day 0 | 70, 21 | 63, 91 | 88, 8 | 87, 35 | 77.56 +/- 12.41 |
| Post-Expansion Day 8 | 92, 12 | 95, 63 | 94, 88 | 92, 83 | 93.86 +/- 1.65 |
***
7-AAD viability: 7-Aminoactinomycin viability, SD: Standard Deviation;
***
p: p-value.